SUNNYVALE, California,
June 20, 2017 /PRNewswire/ --
The French Cancer
Institute is Building its
Re-irradiation and Adaptive
Radiotherapy Program Using
the Latest Technology
Developed by Accuray
Accuray Incorporated (NASDAQ: ARAY) announced today that the
University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is
providing advanced radiation treatments to cancer patients using
the uniquely smart Radixact™ Treatment Delivery System, the first
to be installed in France. The
IUCT Oncopole began treating patients in January with this new
system, designed to deliver image-guided intensity-modulated
radiation therapy (IG-IMRT), an extremely precise form of radiation
therapy.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://mma.prnewswire.com/media/522076/Accuray_Radixac_Treatment_Delivery_System.jpg
)
"The acquisition of innovative equipment, including the Radixact
System, is part of our strategy to offer best-in-class cancer care
to all patients in the region", said Professor Elizabeth Moyal, Head of the Radiotherapy
Department at the IUCT Oncopole. "What makes the Radixact
technology so special is that its sophisticated tools enable us to
use progressive clinical approaches such as re-irradiation and
adaptive therapy to ensure patients receive the optimal treatment
for them, at every stage of their cancer journey."
The benefits of the Radixact
System: an innovative technology
created to empower clinicians to improve their
patients' care
The Radixact System is the next generation TomoTherapy®
platform. Fully integrated with the Accuray Precision™ Treatment
Planning System and the iDMS™ Data Management System, the system
enables clinicians to achieve the best possible treatment outcomes
today and for years to come.
The Radixact System has been designed to facilitate faster image
acquisition and treatment delivery, allowing the clinical team to
provide precise radiation treatments to more patients, every day.
The system features a more powerful linear accelerator, low-dose
fan beam MVCT imaging and unique helical delivery technology, so
clinicians can apply highly conformal and homogenous dose
distributions to any target volume, while minimizing dose to
surrounding normal healthy tissue, during each treatment fraction.
Smart, automated workflows and midcourse decision-making tools
enable clinicians to adapt delivery to changes in tumor size, shape
and location within the patient.
The Radixact System is capable of treating all standard
radiation therapy indications such as brain, breast, head and neck,
prostate, and rectal and spine cancers, in addition to complex
treatments such as total marrow irradiation. It is so precise that,
should the cancer re-occur, the patient can be re-treated on the
Radixact System. As explained by Prof. Moyal, "We have successfully
administered treatment for several types of cancers so far
including breast cancer, head and neck cancers, and pediatric
tumors which we previously treated on a routine basis using the
TomoTherapy System. Moving forward we plan to use the Radixact
System to provide treatment for abdominal, hematologic and pelvic
tumors, indications which will also benefit from the system's
advanced adaptive therapy capabilities."
"We are very proud to partner with IUCT Oncopole to enhance the
quality of care for cancer patients in France. Prof. Moyal and her team are
demonstrating that the Radixact™ System can successfully be used as
a mainstream radiation therapy option, enabling them to provide
effective treatments for patients with a diverse range of clinical
needs," says Lionel Hadjadjeba, Senior Vice President, and Chief
Commercial Officer at Accuray.
About the University Cancer Institute of Toulouse Oncopole (IUCT
Oncopole)
The IUCT Oncopole is comprised of the Institut Claudius Regaud,
a cancer center, and several teams from Toulouse University
Hospital Center. The two institutions offer the expertise of 1,400
professionals specialized in oncology on the same site.
Located in the heart of a campus grouping together public and
private stakeholders, it is involved in the fight against cancer.
Indeed, the IUCT Oncopole is a new way to think of cancer
healthcare. To the healthcare and public health missions of this
property is added a top priority: Innovation and research for the
benefit of the patient.
The IUCT Oncolope gathers all the oncological specialties
required to detect, treat, and monitor disease: surgery, medicine,
radiotherapy and brachytherapy, nuclear medicine, interventional
imaging, biology and anatomical pathology. Its Radiotherapy
Department, that treats 3,000 patients annually, is led by Prof.
Elizabeth Moyal. It is equipped with
7 accelerators, including 2 TomoTherapy® Systems and one
Radixact System.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and Accuray's
leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016 and February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.